FOXO4-DRI vs Alpha-GPC
Side-by-side comparison of key properties, dosing, and research.
- Summary
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Alpha-GPC is the most bioavailable form of choline, readily crossing the blood-brain barrier to rapidly increase acetylcholine levels. It enhances cognitive performance, supports GH secretion, and is used as an essential complement to many nootropic peptides (especially those that increase acetylcholine demand like Noopept and Dihexa).
- Half-Life
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- ~4–6 hours
- Admin Route
- Subcutaneous, Intraperitoneal (research)
- Oral, SubQ
- Research
- —
- —
- Typical Dose
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- 300–600 mg
- Frequency
- 3 consecutive days per cycle
- 1–2x daily
- Key Benefits
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Rapidly raises brain acetylcholine levels
- Enhances memory formation and recall
- Prevents headaches from nootropic peptides (choline donor)
- Stimulates growth hormone secretion (modest)
- Improves attention and processing speed
- Neuroprotective in Alzheimer's and cognitive decline
- Approved in Europe for Alzheimer's therapy
- Enhances power output in athletes (pre-workout)
- Side Effects
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Headache (paradoxically, from excess acetylcholine at very high doses)
- Nausea at doses > 1200 mg
- Dizziness
- Fatigue at high doses
- +1 more
- Stacks With
- —
- —